Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK

June 10, 2026 5:19 AM

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found